CymaBay Therapeutics Inc (NASDAQ:CBAY) – Analysts at Leerink Swann reduced their FY2019 EPS estimates for CymaBay Therapeutics in a research report issued to clients and investors on Tuesday. Leerink Swann analyst J. Schwartz now anticipates that the biopharmaceutical company will post earnings of ($1.13) per share for the year, down from their previous forecast of ($1.06). Leerink Swann currently has a “Buy” rating and a $16.00 price objective on the stock.

CymaBay Therapeutics (NASDAQ:CBAY) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). During the same quarter last year, the business earned ($0.25) EPS.

A number of other research firms have also recently issued reports on CBAY. Oppenheimer set a $15.00 price target on CymaBay Therapeutics and gave the stock a “buy” rating in a report on Monday, October 30th. Piper Jaffray Companies restated a “buy” rating and set a $12.00 price target on shares of CymaBay Therapeutics in a report on Friday, October 27th. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of CymaBay Therapeutics in a report on Tuesday. Cantor Fitzgerald restated a “buy” rating and set a $16.00 price target on shares of CymaBay Therapeutics in a report on Wednesday, November 8th. Finally, BidaskClub cut CymaBay Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 3rd. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $14.50.

CymaBay Therapeutics (NASDAQ CBAY) traded up $0.22 during trading on Thursday, hitting $8.66. The company’s stock had a trading volume of 667,537 shares, compared to its average volume of 724,597. CymaBay Therapeutics has a 52-week low of $1.46 and a 52-week high of $9.40. The company has a current ratio of 7.39, a quick ratio of 7.39 and a debt-to-equity ratio of 0.04.

A number of large investors have recently modified their holdings of CBAY. Bank of New York Mellon Corp lifted its stake in CymaBay Therapeutics by 0.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 140 shares in the last quarter. Marshall Wace North America L.P. bought a new position in CymaBay Therapeutics during the 2nd quarter valued at $242,000. Ardsley Advisory Partners lifted its stake in CymaBay Therapeutics by 66.2% during the 2nd quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock valued at $290,000 after acquiring an additional 20,000 shares in the last quarter. Boothbay Fund Management LLC bought a new position in CymaBay Therapeutics during the 3rd quarter valued at $404,000. Finally, Crestline Management LP bought a new position in CymaBay Therapeutics during the 3rd quarter valued at $841,000. Institutional investors and hedge funds own 68.77% of the company’s stock.

In other news, SVP Charles Mcwherter bought 5,000 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The shares were bought at an average cost of $8.67 per share, for a total transaction of $43,350.00. Following the acquisition, the senior vice president now directly owns 10,300 shares in the company, valued at $89,301. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kurt Von Emster sold 108,876 shares of the stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $7.85, for a total value of $854,676.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 447,257 shares of company stock worth $3,730,862. 15.10% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “CymaBay Therapeutics Inc to Post FY2019 Earnings of ($1.13) Per Share, Leerink Swann Forecasts (CBAY)” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/11/30/cymabay-therapeutics-inc-to-post-fy2019-earnings-of-1-13-per-share-leerink-swann-forecasts-cbay.html.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Earnings History and Estimates for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Stock Ratings for CymaBay Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc and related stocks with our FREE daily email newsletter.